Investor Presentaiton

FY 2022/23 guidance - organic growth is now expected around 8% and the reported EBIT margin is now expected in the 28-29%* range Organic revenue growth Reported revenue growth in DKK Reported EBIT margin* Effective tax rate Capital expenditures *before special items related to the Atos Medical integration (expected around 50 million DKK in FY 2022/23) 9 Around 8% 8-9% 28-29% Around 21% Around 1.4 bn DKK Coloplast

View entire presentation